Subcutaneous Extended-Release Buprenorphine Use in Pregnancy

Table 1

Urine buprenorphine and norbuprenorphine levels for patient one obtained through gestation, at delivery, and 8 weeks postdelivery—the last administration of subcutaneous extended-release buprenorphine was at 17^4/7 weeks’ gestation.

Gestational age; (weeks)	Buprenorphine level; (ng/mg creatinine)	Norbuprenorphine level; (ng/mg creatinine)
22^4/7	111	313
25^5/7	85	156
28^6/7	90	155
32^6/7	64	88
35^5/7	67	101
37^5/7	59	104
Delivery 39^3/7	43	87
8 weeks postdelivery	11	24